


PHARMACEUTICAL 2017

Fibrocell Science Inc
Rank 218 of 308



The relative strengths and weaknesses of Fibrocell Science Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fibrocell Science Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Fibrocell Science Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 175%, being 70% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	18,028
Cost of Goods Sold	697
Intangible Assets	0
Liabilities, Current	2,987
Liabilities, Non-Current	0
Other Assets	65
Other Compr. Net Income	0
Other Expenses	4,463
Other Liabilities	8,734
Other Net Income	11,377
Other Revenues	355
Property and Equipment	1,489
Research and Development	8,400
Selling, General and Administrative Expense	9,773

Output Variable	Value in 1000 USD
Assets	19,582
Liabilities	11,721
Expenses	23,333
Revenues	355
Stockholders Equity	7,861
Net Income	-11,601
Comprehensive Net Income	-11,601
BaseVar	33,184
ECR before LimitedLiability	35%
Economic Capital Ratio	175%